MORE►
Vertex Pharmaceuticals
Panelists at the BioNTX summit family office discussion included, from left, Timothy Morris of Aacolade Pharma, Vic Stone of Alloy Therapeutics, Justin Yang of GHIC, and Yizhen Dong of Echo Investment Capital. The discussion was moderated by Weaver’s Tyler Ridley. [Photo: BioNTX]
Keys to Tapping Family Office Money: Pinpoint Their Passion, and ‘One Meeting in Person Equals 1,000 Emails’
by Glenn Hunter | Oct 24, 2024
Fundraising has slowed and valuations are down, but biotech founders could have a lifeline in family office investments, panelists at the recent BioNTX summit in Arlington agreed. They said succeeding with these investors can take time, a lot of education, and a compelling, well-crafted story that connects emotionally with the family.
by David Seeley |
Dec 11, 2023
On Friday, the first CRISPR-based gene-editing therapy to win FDA approval was announced. CASGEVY holds "the potential of a functional cure" for sickle cell disease—and Medical City Children’s is one of only nine hospitals in the U.S. in its initial network of authorized treatment centers.
MORE►
by Quincy Preston |
Jul 26, 2023
From an old car parts garage, Vertex Founder Joshua Boger launched the Boston-based biotech giant in 1989, running it for two decades as CEO. Boger "unretired" in June to join fast-moving Alkeus Pharmaceuticals as executive chairman.
In Dallas, he shared the "mistakes" that led to his success with innovators at Pegasus Park. Here's his no-holds-barred dose of truth for all entrepreneurs.
In Dallas, he shared the "mistakes" that led to his success with innovators at Pegasus Park. Here's his no-holds-barred dose of truth for all entrepreneurs.
MORE►
